Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer].

Zhonghua yi xue za zhi - 20 Nov 2007

Wang Yan, Zhang Xiang-Ru, Zhu Hong-Xia, Wang Bin, Xu Ning-Zhi, Sun Yan

Abstract excerpt

OBJECTIVE: To establish a model to predict the clinical response of Gefitinib in non-small cell lung cancer (NSCLC). METHODS: The clinical outcomes of 262 consecutive advanced NSCLC patients to oral treatment of gefitinib 250 mg daily in the past 4 years were reviewed. DNA sequencing was used to detect the mutations in the exons 18, 19, 20, and 21 of the epidermal growth factor receptor (EGFR) tyrosine kinase...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Follow-Up Studies

Share to Gefitinib

Share to Neoplasm Staging

Share to Proportional Hazards Models

Share to Quinazolines

Source

Identifiers

PMID: 18261354

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Establishment of a model to assess the clinical efficacy of Gefitinib in treatment of non-small cell lung cancer].PMID 18261354Read ↗

[Association of serum EGFR protein concentration with the efficacy of Gefitinib in the treatment of advanced non-small cell lung cancer].Semantic proximity Read ↗

Effect of gefitinib challenge to initial treatment with non-small cell lung cancer.Semantic proximity Read ↗

Clinical predictors versus epidermal growth factor receptor mutation in gefitinib-treated non-small-cell lung cancer patients.Semantic proximity Read ↗

[Relationship of the curative effects of gefitinib on non-small cell lung carcinoma to gender and to epithelial growth factor receptor status].Semantic proximity Read ↗

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839)Semantic proximity Read ↗

Gefitinib treatment for non-small cell lung cancer -- a study including patients with poor performance status.Semantic proximity Read ↗

[Effectiveness of gefitinib (Iressa) as first-line therapy for inoperable non-small-cell lung cancer with mutated EGFR gene (phase II study)].Semantic proximity Read ↗

[Correlation of epidermal growth factor receptor mutations and HER2/3 protein expression with clinical outcome in advanced non-small cell lung cancer patients treated with gefitinib].Semantic proximity Read ↗

[A study on the long-term non-small cell lung cancer survivors in the Expand Access Program of gefitinib in China].Semantic proximity Read ↗

Histoculture drug response assay for gefitinib in non-small-cell lung cancer.Semantic proximity Read ↗

[Effect of rs2293347 Polymorphism in EGFR on the Clinical Efficacy of Gefitinib in Patients with Non-small Cell Lung Cancer].Semantic proximity Read ↗

Predictive factors associated with prolonged survival in patients with advanced non-small-cell lung cancer (NSCLC) treated with gefitinib.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.